Effect of a New Fish Oil Concentrate (OMACOR) on Plasma Lipids and Lipoproteins in Patients with Hypertriglyceridaemia

Mackness, Mike; Bhatnagar, Deepak; Prais, H; Haynes, B. W.; Morgan, J.G.; Durrington, PN

doi:10.1042/cs089016pc

Cited by 28 publications

(41 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fish oil has several effects on lipid metabolism, most notably a reduction of triacylglycerol concentrations due to diminished hepatic synthesis (Mackness et al, 1994;Eritsland et al, 1995). Data on apoB kinetics are limited: Nestel et al, 1984 reported that ®sh oil supplementation reduced VLDL apoB synthesis using a radioisotopic technique.…”

Section: Discussionmentioning

confidence: 99%

Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males

et al. 1998

View full text Add to dashboard Cite

Objective: To evaluate the effects of four weeks of ®sh oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males. Design and subjects: Very low density lipoprotein (VLDL) apolipoprotein B100 (apoB100) kinetics in ten healthy, white males, aged 22±43 y (mean 32 y) were investigated using a 13 C-leucine technique and gas chromatography-mass spectrometry before and after ®sh oil supplementation. Intervention: All subjects received 10 g (1.8 g EPA, 1.2 g DHA)ad of ®sh oil concentrate for four weeks. Results: Fish oil supplementation resulted in a decrease of total plasma VLDL (mean AE s.d. 1.11 AE 0.41 vs 0.87 AE 0.28 mmolal, P`0.05) and triacylglycerol concentrations (0.74 AE 0.27 vs 0.48 AE 0.21 mmolal, P`0.01). VLDL apoB100 pool size was decreased without alteration of the fractional synthetic rate but a signi®cant decrease of apoB100 production (2.23 AE 0.90 vs 1.54 AE 0.52 mgadlah, P`0.02). Following ®sh oil supplementation plasma concentrations of glucose and insulin as well as lipoprotein and hepatic lipase activities were unchanged. Fasting plasma concentrations of non-esteri®ed fatty acid (NEFA) were decreased (0.45 AE 0.12 vs 0.33 AE 0.10 mmolal, P`0.05). Conclusions: Dietary supplementation with ®sh oil in healthy males results in decreased VLDL-triacylglycerol concentrations through a decrease in VLDL particle synthesis. The decrease in NEFA substrate supply also contributes. Sponsorship: Fish oil (Maxepa 1 ) was supplied by Seven Seas Ltd, Hull, England, free of charge. Dr OAF Bodamer was funded by the`Deutsche Forschungsgemeinschaft' (Bo 1193a1-2).

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males

et al. 1998

View full text Add to dashboard Cite

show abstract

“…Subsequent evaluation of the abstract and methods sections led to exclusion of 46 studies. Reasons for exclusion included the following: publications that did not assess fish oil supplementation (15 articles [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]), nonrandomized studies (11 articles [34][35][36][37][38][39][40][41][42][43][44]), the population had patients without diabetes or patients with type 1 diabetes (8 articles [45][46][47][48][49][50][51][52]), duplicate publications (7 articles [53][54][55][56][57][58][59]), studies that did not include a placebo arm (3 articles [60][61][62]), and 1 study that did not include human subjects (63). The 12-month follow-up report of the Italian Multicenter Fish Oil Study (64) was excluded because it is a nonrandomiz...…”

Section: Search Resultsmentioning

confidence: 99%

Fish oil supplementation in type 2 diabetes: a quantitative systematic review.

et al. 2000

View full text Add to dashboard Cite

Abbreviations: DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HMG-CoA, 3-hydroxy 3-methylglutaryl CoA.A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many other substances. Fish Oil Supplementation in Type 2 DiabetesA quantitative systematic review R E V I E W A R T I C L EOBJECTIVE -To determine the effects of fish oil supplementation on lipid levels and glycemic control in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS-A comprehensive search of Medline, Embase, Lilacs, the Cochrane Clinical Trials Registry, bibliographies of relevant papers, and expert input updated through September 1998 was undertaken. All randomized placebo-controlled trials were included in which fish oil supplementation was the only intervention in subjects with type 2 diabetes. Three investigators performed data extraction and quality scoring independently with discrepancies resolved by consensus. Eighteen trials including 823 subjects followed for a mean of 12 weeks were included. Doses of fish oil used ranged from 3 to 18 g/day.The outcomes studied were glycemic control and lipid levels.RESULTS -Meta-analysis of pooled data demonstrated a statistically significant effect of fish oil on lowering triglycerides (Ϫ0.56 mmol/l [95% CI Ϫ0.71 to Ϫ0.41]) and raising LDL cholesterol (0.21 mmol/l [0.02 to 0.41]). No statistically significant effect was observed for fasting glucose, HbA 1c , total cholesterol, or HDL cholesterol. The triglyceride-lowering effect and the elevation in LDL cholesterol were most marked in those trials that recruited hypertriglyceridemic subjects and used higher doses of fish oil. Heterogeneity was observed and explained by the recruitment of subjects with baseline hypertriglyceridemia in some studies. CONCLUSIONS R e v i e w s / C o m m e n t a r i e s / P o s i t i o n S t a t e m e n t s 1408DIABETES CARE, VOLUME 23, NUMBER 9, SEPTEMBER 2000 Fish oil in type 2 diabetesOutcome measures and data extraction Study selection, data extraction, and assigning of a quality score were undertaken independently by 3 investigators with discrepancies resolved by consensus. When data were not available in a published report, efforts were made to contact the primary investigators. Data related to the effects of fish oil and placebo on glycemic and lipid outcomes were extracted from each trial. One study reported total glycosylated hemoglobin; a formula was used to convert data to HbA 1c (15). Study quality was assessed using the score developed by Jadad et al. (16), which has a possible range of 0-5, with a cutoff of 2 used to designate studies of high versus low quality. Data analysis and statistical methodsExtracted data were analyzed using the Review Manager 3.1 statistical software developed by the Cochrane Collaboration.A random-effects model was used to pool data. Effect sizes are presented as weighted mean differences with 95% CIs. Heterogeneity was assessed using the 2 method. Publication bias was evaluated using a funnel plot method (1...

show abstract

“…A role of PON1 in vascular disease is strongly supported by knockout and transgenic mouse studies (6,7). The inhibition of LDL oxidation by HDL, due to metabolism of bioactive lipid hydroperoxidases, appears to be partially attributable to PON1 (8)(9)(10)(11). Paraoxonase has been reported to reduce mildly oxidized phospholipids by eliminating these hydroperoxy derivatives of unsaturated fatty acids (9).…”

mentioning

confidence: 89%

“…The inhibition of LDL oxidation by HDL, due to metabolism of bioactive lipid hydroperoxidases, appears to be partially attributable to PON1 (8)(9)(10)(11). Paraoxonase has been reported to reduce mildly oxidized phospholipids by eliminating these hydroperoxy derivatives of unsaturated fatty acids (9). Watson et al (10) reported that inactivation of PON1 reduces the ability of HDL to inhibit LDL modification and also reduces the ability of HDL to inhibit monocyte-endothelial interactions, both of which may be important in the inflammatory response in artery wall cells that promotes atherogenesis.…”

mentioning

confidence: 99%

TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease

Carlson

Heagerty

Hatsukami

et al. 2006

Journal of Lipid Research

View full text Add to dashboard Cite

Paraoxonase 1 (PON1) activity is consistently predictive of vascular disease, although the genotype at four functional PON1 polymorphisms is not. To address this inconsistency, we investigated the role of all common PON1 genetic variability, as measured by tagging single-nucleotide polymorphisms (tagSNPs), in predicting PON1 activity for phenylacetate hydrolysis, LDL susceptibility to oxidation ex vivo, plasma homocysteine (Hcy) levels, and carotid artery disease (CAAD) status. The biological goal was to establish whether additional common genetic variation beyond consideration of the four known functional SNPs improves prediction of these phenotypes. PON2 and PON3 tagSNPs were secondarily evaluated. Expanded analysis of an additional 26 tagSNPs found evidence of previously undescribed common PON1 polymorphisms that affect PON1 activity independently of the four known functional SNPs. PON1 activity was not significantly correlated with LDL oxidative susceptibility, but genotypes at the PON1 -108 promoter polymorphism and several other PON1 SNPs were. Neither PON1 activity nor PON1 genotype was significantly correlated with plasma Hcy levels. This study revealed previously undetected common functional PON1 polymorphisms that explain 4% of PON1 activity and a high rate of recombination in PON1, but the sum of the common PON1 locus variation does not explain the relationship between PON1 activity and

show abstract

Effect of a New Fish Oil Concentrate (OMACOR) on Plasma Lipids and Lipoproteins in Patients with Hypertriglyceridaemia

Cited by 28 publications

References 0 publications

Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males

Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males

Fish oil supplementation in type 2 diabetes: a quantitative systematic review.

TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease

Contact Info

Product

Resources

About